| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 56 | 2023 | 124 | 8.460 |
Why?
|
| Stomach Neoplasms | 31 | 2023 | 192 | 5.100 |
Why?
|
| Opium | 20 | 2023 | 21 | 4.450 |
Why?
|
| Iran | 91 | 2023 | 183 | 4.300 |
Why?
|
| Carcinoma, Squamous Cell | 30 | 2022 | 176 | 3.990 |
Why?
|
| Adenocarcinoma | 27 | 2019 | 239 | 3.340 |
Why?
|
| Risk Factors | 100 | 2024 | 3414 | 2.680 |
Why?
|
| Cardiovascular Diseases | 20 | 2024 | 628 | 2.520 |
Why?
|
| Neoplasms | 22 | 2024 | 1033 | 2.120 |
Why?
|
| Helicobacter pylori | 12 | 2015 | 105 | 2.070 |
Why?
|
| Cohort Studies | 54 | 2024 | 1422 | 2.050 |
Why?
|
| Middle Aged | 127 | 2024 | 9642 | 1.980 |
Why?
|
| Humans | 200 | 2024 | 34853 | 1.950 |
Why?
|
| Helicobacter Infections | 10 | 2015 | 74 | 1.900 |
Why?
|
| Diet | 21 | 2024 | 747 | 1.850 |
Why?
|
| Aged | 95 | 2023 | 6448 | 1.800 |
Why?
|
| Male | 145 | 2024 | 18870 | 1.760 |
Why?
|
| Opioid-Related Disorders | 10 | 2023 | 112 | 1.720 |
Why?
|
| Case-Control Studies | 46 | 2023 | 1056 | 1.660 |
Why?
|
| Female | 136 | 2024 | 19873 | 1.560 |
Why?
|
| Prospective Studies | 41 | 2024 | 1353 | 1.530 |
Why?
|
| Drug Users | 3 | 2016 | 42 | 1.510 |
Why?
|
| Adult | 92 | 2024 | 11034 | 1.410 |
Why?
|
| Carcinogens | 5 | 2020 | 117 | 1.400 |
Why?
|
| Mortality | 9 | 2021 | 150 | 1.390 |
Why?
|
| Incidence | 33 | 2023 | 882 | 1.260 |
Why?
|
| Ilex paraguariensis | 4 | 2018 | 4 | 1.210 |
Why?
|
| Registries | 5 | 2021 | 330 | 1.170 |
Why?
|
| Environmental Exposure | 9 | 2022 | 207 | 1.150 |
Why?
|
| Smoking | 24 | 2022 | 903 | 1.100 |
Why?
|
| Opiate Alkaloids | 5 | 2023 | 8 | 1.050 |
Why?
|
| Digestive System Diseases | 2 | 2014 | 4 | 0.980 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 336 | 0.980 |
Why?
|
| Epidemiologic Studies | 4 | 2019 | 31 | 0.980 |
Why?
|
| Research Design | 6 | 2018 | 292 | 0.960 |
Why?
|
| Proportional Hazards Models | 18 | 2024 | 423 | 0.910 |
Why?
|
| Early Detection of Cancer | 2 | 2017 | 292 | 0.910 |
Why?
|
| Risk Assessment | 18 | 2021 | 727 | 0.890 |
Why?
|
| Gastroesophageal Reflux | 8 | 2022 | 29 | 0.850 |
Why?
|
| Models, Statistical | 3 | 2013 | 171 | 0.850 |
Why?
|
| Odds Ratio | 17 | 2017 | 517 | 0.820 |
Why?
|
| Coronary Stenosis | 1 | 2021 | 36 | 0.810 |
Why?
|
| Analgesics, Opioid | 6 | 2023 | 176 | 0.810 |
Why?
|
| Cause of Death | 7 | 2023 | 154 | 0.780 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 147 | 0.740 |
Why?
|
| Follow-Up Studies | 18 | 2020 | 964 | 0.730 |
Why?
|
| Cardia | 5 | 2015 | 5 | 0.720 |
Why?
|
| Colorectal Neoplasms | 7 | 2023 | 413 | 0.720 |
Why?
|
| Epidemiologic Methods | 4 | 2013 | 44 | 0.720 |
Why?
|
| Tea | 7 | 2019 | 41 | 0.720 |
Why?
|
| Tooth Loss | 6 | 2024 | 35 | 0.700 |
Why?
|
| Adiposity | 2 | 2023 | 145 | 0.690 |
Why?
|
| Pepsinogen A | 5 | 2011 | 5 | 0.670 |
Why?
|
| Hot Temperature | 6 | 2019 | 120 | 0.670 |
Why?
|
| Alcohol Drinking | 11 | 2017 | 490 | 0.670 |
Why?
|
| Occult Blood | 1 | 2017 | 25 | 0.640 |
Why?
|
| Polymorphism, Genetic | 5 | 2009 | 165 | 0.630 |
Why?
|
| Pancreatic Neoplasms | 5 | 2019 | 106 | 0.620 |
Why?
|
| SEER Program | 1 | 2017 | 87 | 0.610 |
Why?
|
| Anticarcinogenic Agents | 2 | 2015 | 65 | 0.610 |
Why?
|
| Respiration Disorders | 1 | 2016 | 10 | 0.590 |
Why?
|
| Prevalence | 16 | 2023 | 1425 | 0.590 |
Why?
|
| Risk Reduction Behavior | 2 | 2015 | 121 | 0.580 |
Why?
|
| Sample Size | 2 | 2013 | 28 | 0.580 |
Why?
|
| Meat | 6 | 2022 | 41 | 0.570 |
Why?
|
| Ghrelin | 4 | 2019 | 12 | 0.540 |
Why?
|
| Causality | 2 | 2012 | 45 | 0.530 |
Why?
|
| Retrospective Studies | 14 | 2022 | 1961 | 0.530 |
Why?
|
| Life Style | 6 | 2021 | 288 | 0.520 |
Why?
|
| Obesity | 5 | 2023 | 965 | 0.500 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 2333 | 0.500 |
Why?
|
| Body Mass Index | 10 | 2023 | 775 | 0.490 |
Why?
|
| Beverages | 3 | 2009 | 64 | 0.490 |
Why?
|
| Papillomavirus Infections | 4 | 2022 | 316 | 0.490 |
Why?
|
| Oral Health | 5 | 2021 | 61 | 0.480 |
Why?
|
| Survival Rate | 7 | 2017 | 310 | 0.480 |
Why?
|
| Age Factors | 9 | 2021 | 1007 | 0.480 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2020 | 18 | 0.480 |
Why?
|
| Nutritional Sciences | 1 | 2013 | 21 | 0.470 |
Why?
|
| Feeding Behavior | 5 | 2018 | 418 | 0.460 |
Why?
|
| Food | 3 | 2023 | 95 | 0.460 |
Why?
|
| Pepsinogen C | 2 | 2011 | 2 | 0.460 |
Why?
|
| Biomedical Research | 5 | 2023 | 371 | 0.450 |
Why?
|
| Social Class | 7 | 2017 | 228 | 0.450 |
Why?
|
| Epidemiology | 1 | 2012 | 6 | 0.450 |
Why?
|
| Risk | 7 | 2017 | 256 | 0.440 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 15 | 0.440 |
Why?
|
| Smoking Cessation | 5 | 2023 | 487 | 0.440 |
Why?
|
| Precancerous Conditions | 6 | 2015 | 81 | 0.430 |
Why?
|
| Hypertension | 5 | 2022 | 770 | 0.430 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 35 | 0.420 |
Why?
|
| Antigens, Bacterial | 5 | 2015 | 129 | 0.420 |
Why?
|
| Logistic Models | 14 | 2022 | 894 | 0.420 |
Why?
|
| China | 9 | 2019 | 178 | 0.410 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 3 | 0.410 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 29 | 0.400 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 14 | 0.390 |
Why?
|
| alpha-Tocopherol | 5 | 2012 | 25 | 0.390 |
Why?
|
| Pepsinogens | 1 | 2010 | 1 | 0.390 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2022 | 63 | 0.380 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 181 | 0.380 |
Why?
|
| Stomach | 1 | 2010 | 43 | 0.380 |
Why?
|
| beta Carotene | 4 | 2012 | 11 | 0.370 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 20 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 638 | 0.370 |
Why?
|
| Esophagogastric Junction | 5 | 2012 | 7 | 0.360 |
Why?
|
| Time Factors | 9 | 2021 | 1681 | 0.360 |
Why?
|
| Vitamins | 4 | 2015 | 91 | 0.360 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 756 | 0.360 |
Why?
|
| Sex Factors | 7 | 2021 | 859 | 0.350 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 112 | 0.340 |
Why?
|
| Educational Status | 5 | 2020 | 295 | 0.340 |
Why?
|
| Skin Diseases | 1 | 2009 | 32 | 0.340 |
Why?
|
| Secondary Prevention | 2 | 2019 | 37 | 0.340 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 794 | 0.340 |
Why?
|
| Drinking | 2 | 2019 | 37 | 0.340 |
Why?
|
| Finland | 6 | 2017 | 10 | 0.340 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 2561 | 0.340 |
Why?
|
| Air Pollutants | 2 | 2022 | 90 | 0.330 |
Why?
|
| Hepatitis C | 2 | 2020 | 120 | 0.330 |
Why?
|
| Glucuronates | 4 | 2013 | 6 | 0.330 |
Why?
|
| Tobacco, Smokeless | 4 | 2019 | 18 | 0.330 |
Why?
|
| Venous Thrombosis | 2 | 2020 | 27 | 0.330 |
Why?
|
| Chemoprevention | 3 | 2007 | 34 | 0.330 |
Why?
|
| Bacterial Proteins | 5 | 2015 | 520 | 0.320 |
Why?
|
| Nuts | 2 | 2018 | 9 | 0.320 |
Why?
|
| Chronic Disease | 6 | 2016 | 469 | 0.320 |
Why?
|
| Oral Hygiene | 2 | 2021 | 15 | 0.310 |
Why?
|
| Panax | 1 | 2007 | 5 | 0.310 |
Why?
|
| Naphthoquinones | 2 | 2022 | 35 | 0.300 |
Why?
|
| Rural Population | 3 | 2013 | 253 | 0.300 |
Why?
|
| Students | 2 | 2023 | 452 | 0.300 |
Why?
|
| Peer Group | 2 | 2019 | 138 | 0.300 |
Why?
|
| Asthma | 1 | 2011 | 363 | 0.300 |
Why?
|
| Minerals | 3 | 2024 | 45 | 0.290 |
Why?
|
| Phytotherapy | 1 | 2007 | 62 | 0.290 |
Why?
|
| Gastritis, Atrophic | 3 | 2011 | 10 | 0.290 |
Why?
|
| Waist Circumference | 4 | 2023 | 82 | 0.290 |
Why?
|
| Interleukin-1beta | 1 | 2006 | 66 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 178 | 0.280 |
Why?
|
| Regression Analysis | 4 | 2017 | 429 | 0.280 |
Why?
|
| Epidemiologic Research Design | 2 | 2018 | 16 | 0.280 |
Why?
|
| Hepatitis B virus | 1 | 2005 | 13 | 0.270 |
Why?
|
| Hepatitis B, Chronic | 1 | 2005 | 11 | 0.270 |
Why?
|
| Indomethacin | 1 | 2005 | 24 | 0.270 |
Why?
|
| Diet Surveys | 5 | 2019 | 96 | 0.260 |
Why?
|
| Papillomaviridae | 4 | 2022 | 125 | 0.260 |
Why?
|
| Carrier State | 1 | 2005 | 32 | 0.260 |
Why?
|
| Comorbidity | 5 | 2021 | 606 | 0.260 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 1003 | 0.260 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 901 | 0.260 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 252 | 0.250 |
Why?
|
| Diabetes Mellitus | 4 | 2021 | 465 | 0.250 |
Why?
|
| Benzo(a)pyrene | 3 | 2012 | 122 | 0.240 |
Why?
|
| Food Handling | 2 | 2015 | 33 | 0.240 |
Why?
|
| Periodontal Diseases | 2 | 2021 | 49 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2010 | 233 | 0.240 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 555 | 0.240 |
Why?
|
| Environment | 2 | 2019 | 130 | 0.240 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 37 | 0.230 |
Why?
|
| Interleukin-1 | 1 | 2003 | 33 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 592 | 0.230 |
Why?
|
| Trans Fatty Acids | 1 | 2022 | 5 | 0.230 |
Why?
|
| Virus Replication | 1 | 2005 | 261 | 0.230 |
Why?
|
| Carcinoma, Small Cell | 1 | 2022 | 6 | 0.220 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2022 | 4 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2015 | 99 | 0.220 |
Why?
|
| Drug Combinations | 2 | 2020 | 89 | 0.220 |
Why?
|
| Cheese | 1 | 2022 | 3 | 0.220 |
Why?
|
| Coffee | 2 | 2015 | 20 | 0.220 |
Why?
|
| Pyrenes | 4 | 2013 | 24 | 0.220 |
Why?
|
| Intensive Care Units | 1 | 2022 | 57 | 0.220 |
Why?
|
| Gastric Mucosa | 2 | 2015 | 50 | 0.220 |
Why?
|
| Occupational Diseases | 1 | 2022 | 45 | 0.210 |
Why?
|
| Amino Alcohols | 1 | 2022 | 1 | 0.210 |
Why?
|
| Dyspepsia | 2 | 2012 | 5 | 0.210 |
Why?
|
| Lead Poisoning | 1 | 2022 | 24 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2022 | 67 | 0.210 |
Why?
|
| Vegetables | 3 | 2015 | 135 | 0.210 |
Why?
|
| Mutation | 2 | 2020 | 1023 | 0.210 |
Why?
|
| Air Pollution | 1 | 2022 | 59 | 0.210 |
Why?
|
| Dairy Products | 2 | 2022 | 33 | 0.210 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 73 | 0.210 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 570 | 0.200 |
Why?
|
| Dietary Supplements | 3 | 2009 | 196 | 0.200 |
Why?
|
| Postoperative Complications | 2 | 2017 | 206 | 0.200 |
Why?
|
| Asparaginase | 1 | 2021 | 4 | 0.200 |
Why?
|
| Coronary Angiography | 1 | 2021 | 92 | 0.200 |
Why?
|
| Mouth | 1 | 2021 | 44 | 0.200 |
Why?
|
| Nails | 2 | 2018 | 9 | 0.200 |
Why?
|
| Inflammation | 1 | 2006 | 577 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2019 | 60 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2009 | 528 | 0.200 |
Why?
|
| Brucellosis | 1 | 2020 | 8 | 0.200 |
Why?
|
| Q Fever | 1 | 2020 | 7 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 37 | 0.200 |
Why?
|
| ROC Curve | 3 | 2017 | 138 | 0.200 |
Why?
|
| Myocardial Ischemia | 2 | 2018 | 72 | 0.190 |
Why?
|
| Coxiella burnetii | 1 | 2020 | 16 | 0.190 |
Why?
|
| Double-Blind Method | 5 | 2012 | 269 | 0.190 |
Why?
|
| Household Articles | 1 | 2020 | 2 | 0.190 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 685 | 0.190 |
Why?
|
| Government Programs | 1 | 2020 | 28 | 0.190 |
Why?
|
| Plant Leaves | 2 | 2018 | 110 | 0.190 |
Why?
|
| Selenium | 4 | 2017 | 144 | 0.190 |
Why?
|
| Antioxidants | 4 | 2015 | 386 | 0.190 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 30 | 0.190 |
Why?
|
| Patient Discharge | 1 | 2020 | 92 | 0.190 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 18 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2020 | 75 | 0.190 |
Why?
|
| Flavonoids | 1 | 2020 | 78 | 0.180 |
Why?
|
| Developing Countries | 3 | 2018 | 97 | 0.180 |
Why?
|
| Cholecystectomy | 2 | 2017 | 6 | 0.180 |
Why?
|
| Mouth Mucosa | 1 | 2019 | 33 | 0.180 |
Why?
|
| Primary Health Care | 2 | 2020 | 283 | 0.180 |
Why?
|
| Telomerase | 1 | 2020 | 40 | 0.180 |
Why?
|
| Genetic Testing | 1 | 2020 | 71 | 0.180 |
Why?
|
| History of Medicine | 1 | 2019 | 1 | 0.180 |
Why?
|
| Fruit | 2 | 2015 | 159 | 0.180 |
Why?
|
| Family Characteristics | 1 | 2020 | 102 | 0.180 |
Why?
|
| Waist-Hip Ratio | 1 | 2019 | 32 | 0.180 |
Why?
|
| United States | 7 | 2023 | 3894 | 0.180 |
Why?
|
| DNA, Viral | 4 | 2010 | 295 | 0.180 |
Why?
|
| Cultural Diversity | 1 | 2020 | 158 | 0.180 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2020 | 123 | 0.170 |
Why?
|
| Intra-Abdominal Fat | 1 | 2019 | 39 | 0.170 |
Why?
|
| Biopsy | 4 | 2013 | 151 | 0.170 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 98 | 0.170 |
Why?
|
| Pancreatic Fistula | 1 | 2018 | 2 | 0.170 |
Why?
|
| Pancreatectomy | 1 | 2018 | 4 | 0.170 |
Why?
|
| Carcinoma | 1 | 2019 | 94 | 0.170 |
Why?
|
| Hospitalization | 2 | 2022 | 370 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2022 | 984 | 0.170 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 284 | 0.170 |
Why?
|
| Accidents, Traffic | 1 | 2018 | 42 | 0.160 |
Why?
|
| Bacteria | 1 | 2021 | 245 | 0.160 |
Why?
|
| Genotype | 4 | 2012 | 641 | 0.160 |
Why?
|
| Animals | 9 | 2022 | 14307 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 50 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2021 | 436 | 0.160 |
Why?
|
| Stroke | 2 | 2018 | 274 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 64 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2019 | 148 | 0.160 |
Why?
|
| Universities | 1 | 2020 | 363 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2014 | 1349 | 0.150 |
Why?
|
| Sex Characteristics | 2 | 2017 | 213 | 0.150 |
Why?
|
| Colonoscopy | 1 | 2017 | 98 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 77 | 0.150 |
Why?
|
| Community-Based Participatory Research | 2 | 2019 | 292 | 0.150 |
Why?
|
| Torsades de Pointes | 1 | 2016 | 2 | 0.150 |
Why?
|
| Constipation | 1 | 2016 | 5 | 0.150 |
Why?
|
| Prognosis | 6 | 2019 | 707 | 0.150 |
Why?
|
| Dietary Proteins | 1 | 2017 | 30 | 0.150 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 18 | 0.150 |
Why?
|
| Endocrine System Diseases | 1 | 2016 | 12 | 0.150 |
Why?
|
| Hypotension | 1 | 2016 | 21 | 0.150 |
Why?
|
| Body Size | 2 | 2014 | 28 | 0.150 |
Why?
|
| Immune System Diseases | 1 | 2016 | 20 | 0.150 |
Why?
|
| Fuel Oils | 1 | 2016 | 1 | 0.150 |
Why?
|
| Verbal Behavior | 1 | 2016 | 12 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2006 | 31 | 0.140 |
Why?
|
| Food Preferences | 1 | 2017 | 66 | 0.140 |
Why?
|
| Young Adult | 8 | 2021 | 4012 | 0.140 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 166 | 0.140 |
Why?
|
| Mass Screening | 2 | 2017 | 427 | 0.140 |
Why?
|
| Adolescent | 8 | 2021 | 5035 | 0.140 |
Why?
|
| Ethanol | 1 | 2018 | 188 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2009 | 203 | 0.140 |
Why?
|
| Counseling | 1 | 2016 | 105 | 0.140 |
Why?
|
| Ruminants | 3 | 2022 | 6 | 0.140 |
Why?
|
| HIV Infections | 2 | 2020 | 2207 | 0.140 |
Why?
|
| Aggression | 1 | 2016 | 75 | 0.140 |
Why?
|
| Trace Elements | 1 | 2015 | 25 | 0.130 |
Why?
|
| Size Perception | 1 | 2015 | 5 | 0.130 |
Why?
|
| Chi-Square Distribution | 4 | 2012 | 213 | 0.130 |
Why?
|
| ABO Blood-Group System | 1 | 2015 | 5 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 2015 | 6 | 0.130 |
Why?
|
| Sex Distribution | 6 | 2015 | 212 | 0.130 |
Why?
|
| History, Ancient | 3 | 2020 | 11 | 0.130 |
Why?
|
| Systole | 1 | 2015 | 65 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2015 | 46 | 0.130 |
Why?
|
| Neoplasm Staging | 5 | 2016 | 269 | 0.130 |
Why?
|
| Animal Husbandry | 1 | 2014 | 14 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 231 | 0.130 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2015 | 40 | 0.130 |
Why?
|
| Leukemia | 1 | 2015 | 54 | 0.130 |
Why?
|
| Gallbladder | 1 | 2014 | 3 | 0.130 |
Why?
|
| Cholecystitis | 1 | 2014 | 4 | 0.130 |
Why?
|
| Barrett Esophagus | 2 | 2015 | 29 | 0.120 |
Why?
|
| Seroepidemiologic Studies | 2 | 2020 | 67 | 0.120 |
Why?
|
| Delivery of Health Care | 3 | 2013 | 254 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2015 | 97 | 0.120 |
Why?
|
| Laparoscopes | 1 | 2013 | 1 | 0.120 |
Why?
|
| Hernia, Ventral | 1 | 2013 | 3 | 0.120 |
Why?
|
| Gallbladder Diseases | 1 | 2013 | 3 | 0.120 |
Why?
|
| Health Surveys | 2 | 2014 | 358 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2013 | 6 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 133 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 48 | 0.120 |
Why?
|
| Phenotype | 2 | 2015 | 650 | 0.120 |
Why?
|
| Parturition | 1 | 2013 | 22 | 0.120 |
Why?
|
| Portal Vein | 1 | 2013 | 4 | 0.120 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2013 | 2 | 0.120 |
Why?
|
| Reproductive History | 1 | 2013 | 18 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 445 | 0.120 |
Why?
|
| Nutritional Status | 2 | 2017 | 114 | 0.120 |
Why?
|
| Hematocrit | 1 | 2013 | 18 | 0.120 |
Why?
|
| Awareness | 1 | 2013 | 59 | 0.110 |
Why?
|
| Philosophy | 1 | 2012 | 2 | 0.110 |
Why?
|
| DNA Adducts | 1 | 2012 | 41 | 0.110 |
Why?
|
| Asia | 3 | 2009 | 74 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 145 | 0.110 |
Why?
|
| Food, Preserved | 1 | 2012 | 3 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2012 | 111 | 0.110 |
Why?
|
| Urban Population | 3 | 2013 | 318 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 206 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 424 | 0.110 |
Why?
|
| Patient Selection | 1 | 2013 | 154 | 0.110 |
Why?
|
| Gastric Fundus | 1 | 2011 | 3 | 0.110 |
Why?
|
| Religion | 1 | 2012 | 77 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 111 | 0.110 |
Why?
|
| Gastritis | 1 | 2011 | 11 | 0.110 |
Why?
|
| Gastrins | 1 | 2011 | 9 | 0.110 |
Why?
|
| Genes, p53 | 1 | 2011 | 24 | 0.110 |
Why?
|
| Software | 1 | 2013 | 204 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 4 | 0.100 |
Why?
|
| Peptic Ulcer | 1 | 2011 | 9 | 0.100 |
Why?
|
| DNA Repair | 1 | 2012 | 181 | 0.100 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2011 | 20 | 0.100 |
Why?
|
| Motor Activity | 1 | 2014 | 393 | 0.100 |
Why?
|
| Iron | 1 | 2012 | 204 | 0.100 |
Why?
|
| Autopsy | 1 | 2010 | 40 | 0.100 |
Why?
|
| Atrophy | 1 | 2010 | 40 | 0.100 |
Why?
|
| Health Care Reform | 1 | 2010 | 31 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2011 | 79 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2012 | 250 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 9 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2019 | 51 | 0.090 |
Why?
|
| Confidence Intervals | 4 | 2011 | 151 | 0.090 |
Why?
|
| Mucous Membrane | 1 | 2009 | 34 | 0.090 |
Why?
|
| Copper | 2 | 2024 | 101 | 0.090 |
Why?
|
| Air Pollution, Indoor | 2 | 2020 | 40 | 0.090 |
Why?
|
| Diet Records | 2 | 2021 | 56 | 0.090 |
Why?
|
| History, 19th Century | 2 | 2020 | 24 | 0.090 |
Why?
|
| Tocopherols | 1 | 2009 | 62 | 0.090 |
Why?
|
| Models, Biological | 1 | 2012 | 642 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2009 | 628 | 0.080 |
Why?
|
| Micronutrients | 1 | 2009 | 42 | 0.080 |
Why?
|
| History, 21st Century | 2 | 2020 | 74 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2020 | 110 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 348 | 0.080 |
Why?
|
| Minority Groups | 2 | 2023 | 537 | 0.080 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 75 | 0.080 |
Why?
|
| Acute Disease | 2 | 2021 | 141 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 2128 | 0.080 |
Why?
|
| Biodiversity | 2 | 2021 | 81 | 0.080 |
Why?
|
| Ferritins | 2 | 2022 | 54 | 0.080 |
Why?
|
| Baltimore | 2 | 2020 | 47 | 0.080 |
Why?
|
| Food Contamination | 1 | 2008 | 55 | 0.080 |
Why?
|
| Bile Duct Neoplasms | 1 | 2007 | 3 | 0.080 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2007 | 4 | 0.080 |
Why?
|
| Cholangiocarcinoma | 1 | 2007 | 6 | 0.080 |
Why?
|
| Americas | 1 | 2006 | 6 | 0.070 |
Why?
|
| Goiter | 1 | 2006 | 1 | 0.070 |
Why?
|
| Developed Countries | 1 | 2006 | 12 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2022 | 613 | 0.070 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2006 | 14 | 0.070 |
Why?
|
| Europe | 1 | 2006 | 88 | 0.070 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Antibodies, Bacterial | 2 | 2020 | 107 | 0.070 |
Why?
|
| Glucuronosyltransferase | 1 | 2006 | 25 | 0.070 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2006 | 43 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2006 | 57 | 0.070 |
Why?
|
| Exonucleases | 1 | 2006 | 3 | 0.070 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 83 | 0.070 |
Why?
|
| Receptors, Interleukin | 1 | 2006 | 10 | 0.070 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 49 | 0.070 |
Why?
|
| Carcinogens, Environmental | 1 | 2006 | 34 | 0.070 |
Why?
|
| Interleukins | 1 | 2006 | 28 | 0.070 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2006 | 45 | 0.070 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2006 | 45 | 0.070 |
Why?
|
| Smoke | 1 | 2006 | 39 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2020 | 77 | 0.070 |
Why?
|
| Gastrectomy | 1 | 2005 | 9 | 0.070 |
Why?
|
| Hepatitis B e Antigens | 1 | 2005 | 1 | 0.070 |
Why?
|
| Haplotypes | 1 | 2006 | 152 | 0.070 |
Why?
|
| Water Pollutants, Chemical | 1 | 2008 | 158 | 0.070 |
Why?
|
| Hepatitis B Antibodies | 1 | 2005 | 6 | 0.070 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2005 | 11 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2005 | 18 | 0.070 |
Why?
|
| Water Supply | 2 | 2019 | 54 | 0.060 |
Why?
|
| Brazil | 3 | 2012 | 66 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 195 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2004 | 66 | 0.060 |
Why?
|
| Age Distribution | 4 | 2005 | 223 | 0.060 |
Why?
|
| Body Weights and Measures | 2 | 2018 | 23 | 0.060 |
Why?
|
| Toothbrushing | 1 | 2024 | 8 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2004 | 42 | 0.060 |
Why?
|
| Mouth Neoplasms | 1 | 2005 | 70 | 0.060 |
Why?
|
| Fat Necrosis | 1 | 2003 | 3 | 0.060 |
Why?
|
| Hepatitis | 1 | 2003 | 10 | 0.060 |
Why?
|
| Maryland | 2 | 2019 | 53 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 325 | 0.060 |
Why?
|
| Entrepreneurship | 1 | 2023 | 5 | 0.060 |
Why?
|
| Rural Health | 2 | 2019 | 45 | 0.060 |
Why?
|
| Heartburn | 1 | 2022 | 2 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2003 | 56 | 0.060 |
Why?
|
| Plant Oils | 1 | 2022 | 17 | 0.060 |
Why?
|
| Occupations | 1 | 2022 | 20 | 0.060 |
Why?
|
| Yogurt | 1 | 2022 | 4 | 0.060 |
Why?
|
| Troponin | 1 | 2022 | 15 | 0.060 |
Why?
|
| Substance Abuse Detection | 2 | 2017 | 27 | 0.050 |
Why?
|
| Milk | 1 | 2022 | 48 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2006 | 486 | 0.050 |
Why?
|
| Health Education | 2 | 2018 | 304 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2022 | 49 | 0.050 |
Why?
|
| Radioimmunoassay | 2 | 2011 | 66 | 0.050 |
Why?
|
| Diarrhea | 1 | 2022 | 84 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 531 | 0.050 |
Why?
|
| Microsomes, Liver | 1 | 2022 | 69 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2022 | 107 | 0.050 |
Why?
|
| Reference Values | 2 | 2011 | 204 | 0.050 |
Why?
|
| Antithrombin III | 1 | 2021 | 4 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 608 | 0.050 |
Why?
|
| Linear Models | 3 | 2009 | 253 | 0.050 |
Why?
|
| K562 Cells | 1 | 2020 | 31 | 0.050 |
Why?
|
| U937 Cells | 1 | 2020 | 27 | 0.050 |
Why?
|
| Lead | 1 | 2022 | 87 | 0.050 |
Why?
|
| HL-60 Cells | 1 | 2020 | 32 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 43 | 0.050 |
Why?
|
| Calcium | 1 | 2024 | 445 | 0.050 |
Why?
|
| Liver | 1 | 2003 | 447 | 0.050 |
Why?
|
| Overweight | 1 | 2023 | 233 | 0.050 |
Why?
|
| Kerosene | 1 | 2020 | 1 | 0.050 |
Why?
|
| Heating | 1 | 2020 | 4 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1426 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2022 | 376 | 0.050 |
Why?
|
| Wood | 1 | 2020 | 16 | 0.050 |
Why?
|
| Mice | 2 | 2022 | 5668 | 0.050 |
Why?
|
| Alleles | 2 | 2012 | 284 | 0.050 |
Why?
|
| Biomass | 1 | 2020 | 50 | 0.050 |
Why?
|
| Chromatography, Affinity | 2 | 2013 | 64 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2020 | 59 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2014 | 231 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 181 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2022 | 467 | 0.050 |
Why?
|
| Tretinoin | 1 | 2020 | 50 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2020 | 62 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 139 | 0.050 |
Why?
|
| Enalapril | 1 | 2019 | 6 | 0.050 |
Why?
|
| Placebos | 2 | 2012 | 38 | 0.050 |
Why?
|
| Hydrochlorothiazide | 1 | 2019 | 20 | 0.040 |
Why?
|
| Income | 1 | 2020 | 135 | 0.040 |
Why?
|
| Persia | 1 | 2019 | 1 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2019 | 23 | 0.040 |
Why?
|
| Health Transition | 1 | 2019 | 5 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 63 | 0.040 |
Why?
|
| Middle East | 1 | 2019 | 18 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2006 | 859 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 212 | 0.040 |
Why?
|
| Aspirin | 1 | 2019 | 45 | 0.040 |
Why?
|
| Exercise | 2 | 2017 | 524 | 0.040 |
Why?
|
| Eating | 1 | 2020 | 152 | 0.040 |
Why?
|
| Health Behavior | 2 | 2016 | 491 | 0.040 |
Why?
|
| Nitrosamines | 1 | 2019 | 9 | 0.040 |
Why?
|
| Disabled Persons | 1 | 2019 | 60 | 0.040 |
Why?
|
| Volatile Organic Compounds | 1 | 2019 | 15 | 0.040 |
Why?
|
| Malnutrition | 2 | 2009 | 45 | 0.040 |
Why?
|
| Octreotide | 1 | 2018 | 2 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2018 | 4 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cell Survival | 1 | 2022 | 818 | 0.040 |
Why?
|
| Alkaloids | 1 | 2019 | 38 | 0.040 |
Why?
|
| Urban Health | 1 | 2019 | 86 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2018 | 6 | 0.040 |
Why?
|
| Hair | 1 | 2018 | 20 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 341 | 0.040 |
Why?
|
| Urinalysis | 1 | 2018 | 31 | 0.040 |
Why?
|
| Scandium | 1 | 2017 | 2 | 0.040 |
Why?
|
| Temperature | 1 | 2019 | 275 | 0.040 |
Why?
|
| Chromium | 1 | 2017 | 27 | 0.040 |
Why?
|
| Residence Characteristics | 2 | 2012 | 301 | 0.040 |
Why?
|
| Mercury | 1 | 2017 | 35 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 484 | 0.040 |
Why?
|
| Marriage | 1 | 2017 | 15 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 165 | 0.040 |
Why?
|
| Poultry Products | 1 | 2017 | 1 | 0.040 |
Why?
|
| Eggs | 1 | 2017 | 6 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2017 | 26 | 0.040 |
Why?
|
| History, 15th Century | 1 | 2016 | 1 | 0.040 |
Why?
|
| History, Medieval | 1 | 2016 | 4 | 0.040 |
Why?
|
| History, 16th Century | 1 | 2016 | 4 | 0.040 |
Why?
|
| History, 17th Century | 1 | 2016 | 3 | 0.040 |
Why?
|
| History, 18th Century | 1 | 2016 | 6 | 0.040 |
Why?
|
| Fabaceae | 1 | 2017 | 22 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 2016 | 38 | 0.040 |
Why?
|
| Endosonography | 1 | 2016 | 3 | 0.040 |
Why?
|
| Zinc | 1 | 2017 | 114 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 205 | 0.040 |
Why?
|
| Medical Staff, Hospital | 1 | 2016 | 13 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2022 | 1149 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 53 | 0.030 |
Why?
|
| Nitrate Reductase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Chaperonin 60 | 1 | 2015 | 15 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 288 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 98 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 30 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2015 | 43 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2015 | 5 | 0.030 |
Why?
|
| Factor VIII | 1 | 2015 | 11 | 0.030 |
Why?
|
| Metagenome | 1 | 2015 | 28 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 438 | 0.030 |
Why?
|
| Anthropometry | 1 | 2015 | 91 | 0.030 |
Why?
|
| Magnesium | 1 | 2015 | 95 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2016 | 121 | 0.030 |
Why?
|
| Gangrene | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cholecystitis, Acute | 1 | 2014 | 2 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2005 | 322 | 0.030 |
Why?
|
| Self Concept | 1 | 2015 | 136 | 0.030 |
Why?
|
| Stillbirth | 1 | 2013 | 7 | 0.030 |
Why?
|
| Parity | 1 | 2013 | 46 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2013 | 25 | 0.030 |
Why?
|
| Dentition | 1 | 2013 | 1 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 2013 | 25 | 0.030 |
Why?
|
| Geography | 1 | 2013 | 86 | 0.030 |
Why?
|
| Necrosis | 1 | 2013 | 45 | 0.030 |
Why?
|
| Ischemia | 1 | 2013 | 45 | 0.030 |
Why?
|
| Mastication | 1 | 2012 | 19 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2012 | 7 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 209 | 0.030 |
Why?
|
| Transferrin | 1 | 2012 | 31 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 106 | 0.030 |
Why?
|
| Codon | 1 | 2011 | 38 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 41 | 0.030 |
Why?
|
| Australia | 1 | 2011 | 76 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2011 | 91 | 0.030 |
Why?
|
| Canada | 1 | 2011 | 121 | 0.030 |
Why?
|
| Health Policy | 1 | 2013 | 149 | 0.030 |
Why?
|
| Hospitals | 1 | 2012 | 86 | 0.030 |
Why?
|
| Inpatients | 1 | 2012 | 72 | 0.030 |
Why?
|
| Demography | 1 | 2011 | 167 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 528 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2011 | 69 | 0.020 |
Why?
|
| Morbidity | 1 | 2010 | 94 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 4 | 0.020 |
Why?
|
| Turkmenistan | 1 | 2009 | 1 | 0.020 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2009 | 8 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 20 | 0.020 |
Why?
|
| gamma-Tocopherol | 1 | 2009 | 18 | 0.020 |
Why?
|
| Molybdenum | 1 | 2009 | 14 | 0.020 |
Why?
|
| Riboflavin | 1 | 2009 | 24 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 416 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 480 | 0.020 |
Why?
|
| Zinc Oxide | 1 | 2009 | 16 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 164 | 0.020 |
Why?
|
| Niacin | 1 | 2009 | 23 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 63 | 0.020 |
Why?
|
| Physical Examination | 1 | 2008 | 40 | 0.020 |
Why?
|
| Vitamin A | 1 | 2009 | 87 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 430 | 0.020 |
Why?
|
| Diterpenes | 1 | 2009 | 83 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2009 | 70 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 1503 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 184 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2007 | 16 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 580 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 217 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 58 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2006 | 7 | 0.020 |
Why?
|
| Biotransformation | 1 | 2006 | 65 | 0.020 |
Why?
|
| Exoribonucleases | 1 | 2006 | 8 | 0.020 |
Why?
|
| Cotinine | 1 | 2006 | 40 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2006 | 19 | 0.020 |
Why?
|
| Metaplasia | 1 | 2006 | 34 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 65 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2006 | 61 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 160 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2011 | 874 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 406 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 60 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2005 | 38 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 75 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 114 | 0.020 |
Why?
|
| Ecology | 1 | 2004 | 22 | 0.020 |
Why?
|
| Enzymes | 1 | 2004 | 30 | 0.020 |
Why?
|
| Codeine | 1 | 2004 | 1 | 0.020 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2004 | 2 | 0.020 |
Why?
|
| Hypertriglyceridemia | 1 | 2003 | 13 | 0.020 |
Why?
|
| Morphine | 1 | 2004 | 80 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 35 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2003 | 51 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 639 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2003 | 177 | 0.010 |
Why?
|